Exploitation of protein kinase C: A useful target for cancer therapy

Cancer Treatment Reviews

Volumn 35, Issue 1, 2009, Pages 1-8

  Ali, Ashhar S ^a   Ali, Shadan ^b   El Rayes, Bassel F ^b   Philip, Philip A ^b   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Invasion; Metastasis; PKC isoenzymes

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTISENSE OLIGONUCLEOTIDE; BRYOSTATIN; CURCUMIN; ENZASTAURIN; G PROTEIN COUPLED RECEPTOR; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; LY 379196; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHENOL; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C INHIBITOR; PROTEIN KINASE C ZETA; PROTEIN SERINE THREONINE KINASE; RESVERATROL; ROTTLERIN; SMALL INTERFERING RNA; STAUROSPORINE; STEM CELL FACTOR; TAMOXIFEN; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL TYPE; CELLULAR DISTRIBUTION; CLINICAL TRIAL; COLON CANCER; DRUG TARGETING; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MELANOMA; MULTIPLE MYELOMA; PANCREAS CANCER; PROSTATE CANCER; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; NEOPLASMS; PROTEIN KINASE C;

EID: 58549113975     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.07.006     Document Type: Review

References (86)

1. Castagna M., Takai Y., Kaibuchi K., Sano K., Kikkawa U., and Nishizuka Y. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem 257 (1982) 7847-7851
2. Kikkawa U., Takai Y., Tanaka Y., Miyake R., and Nishizuka Y. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem 258 (1983) 11442-11445
3. Mackay H.J., and Twelves C.J. Targeting the protein kinase C family: are we there yet?. Nat Rev Cancer 7 (2007) 554-562
4. Griner E.M., and Kazanietz M.G. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 7 (2007) 281-294
5. Podar K., Raab M.S., Chauhan D., and Anderson K.C. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Invest Drug 16 (2007) 1693-1707
6. Newton A.C. Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. Biochem J 370 (2003) 361-371
7. Cai H., Smola U., Wixler V., et al. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol 17 (1997) 732-741
8. Marshall C.J. Cell signalling. Raf gets it together. Nature 383 (1996) 127-128
9. Balendran A., Hare G.R., Kieloch A., Williams M.R., and Alessi D.R. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett 484 (2000) 217-223
10. Cacace A.M., Ueffing M., Philipp A., Han E.K., Kolch W., and Weinstein I.B. PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene 13 (1996) 2517-2526
11. Heit I., Wieser R.J., Herget T., et al. Involvement of protein kinase Cdelta in contact-dependent inhibition of growth in human and murine fibroblasts. Oncogene 20 (2001) 5143-5154
12. Wang X.Y., Repasky E., and Liu H.T. Antisense inhibition of protein kinase Calpha reverses the transformed phenotype in human lung carcinoma cells. Exp Cell Res 250 (1999) 253-263
13. O'Brian C., Vogel V.G., Singletary S.E., and Ward N.E. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 49 (1989) 3215-3217
14. Assert R., Kotter R., Bisping G., et al. Anti-proliferative activity of protein kinase C in apical compartments of human colonic crypts: evidence for a less activated protein kinase C in small adenomas. Int J Cancer 80 (1999) 47-53
15. Frey M.R., Saxon M.L., Zhao X., Rollins A., Evans S.S., and Black J.D. Protein kinase C isozyme-mediated cell cycle arrest involves induction of p21(waf1/cip1) and p27(kip1) and hypophosphorylation of the retinoblastoma protein in intestinal epithelial cells. J Biol Chem 272 (1997) 9424-9435
16. Scaglione-Sewell B., Abraham C., Bissonnette M., et al. Decreased PKC-alpha expression increases cellular proliferation, decreases differentiation, and enhances the transformed phenotype of CaCo-2 cells. Cancer Res 58 (1998) 1074-1081
17. Zhu G.H., Wong B.C., Eggo M.C., Yuen S.T., Lai K.C., and Lam S.K. Pharmacological inhibition of protein kinase C activity could induce apoptosis in gastric cancer cells by differential regulation of apoptosis-related genes. Digest Dis Sci 44 (1999) 2020-2026
18. Zhu G.H., Wong B.C., Slosberg E.D., et al. Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. Gastroenterology 118 (2000) 507-514
19. Deacon E.M., Pongracz J., Griffiths G., and Lord J.M. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis. Mol Pathol 50 (1997) 124-131
20. Ono Y., Kikkawa U., Ogita K., et al. Expression and properties of two types of protein kinase C: alternative splicing from a single gene. Science 236 (1987) 1116-1120
21. Jiang X.H., Lam S.K., Lin M.C., et al. Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway. Oncogene 21 (2002) 6113-6122
22. Gokmen-Polar Y., Murray N.R., Velasco M.A., Gatalica Z., and Fields A.P. Elevated protein kinase C betaII is an early promotive event in colon carcinogenesis. Cancer Res 61 (2001) 1375-1381
23. Murray N.R., Weems C., Chen L., et al. Protein kinase C betaII and TGFbetaRII in omega-3 fatty acid-mediated inhibition of colon carcinogenesis. J Cell Biol 157 (2002) 915-920
24. Lee J.Y., Hannun Y.A., and Obeid L.M. Ceramide inactivates cellular protein kinase Calpha. J Biol Chem 271 (1996) 13169-13174
25. Teicher B.A., Alvarez E., Menon K., et al. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule. Cancer Chemoth Pharm 49 (2002) 69-77
26. Graff J.R., McNulty A.M., Hanna K.R., et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615 HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65 (2005) 7462-7469
27. El-Rayes B.F., Ali S., Philip P.A., and Sarkar F.H. Protein kinase C: a target for therapy in pancreatic cancer. Pancreas 36 (2008) 346-352
28. Assender J.W., Gee J.M., Lewis I., Ellis I.O., Robertson J.F., and Nicholson R.I. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 60 (2007) 1216-1221
29. Black J.D. Protein kinase C-mediated regulation of the cell cycle. Front Biosci 5 (2000) D406-D423
30. Wert M.M., and Palfrey H.C. Divergence in the anti-apoptotic signalling pathways used by nerve growth factor and basic fibroblast growth factor (bFGF) in PC12 cells: rescue by bFGF involves protein kinase C delta. Biochem J 352 Part 1 (2000) 175-182
31. Leseux L., Laurent G., Laurent C., et al. PKC {zeta} mTOR pathway: a new target for rituximab therapy in follicular lymphoma. Blood 111 (2008) 285-291
32. Peng Y., Sigua C.A., Gallagher S.F., and Murr M.M. Protein kinase C-zeta is critical in pancreatitis-induced apoptosis of Kupffer cells. J Gastrointest Surg 11 (2007) 1253-1261
33. Lavie Y., Zhang Z.C., Cao H.T., et al. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer 77 (1998) 928-932
34. Doi S., Goldstein D., Hug H., and Weinstein I.B. Expression of multiple isoforms of protein kinase C in normal human colon mucosa and colon tumors and decreased levels of protein kinase C beta and eta mRNAs in the tumors. Mol Carcinogen 11 (1994) 197-203
35. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 308 (1984) 693-698
36. Fang X., Yu S., Tanyi J.L., Lu Y., Woodgett J.R., and Mills G.B. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22 (2002) 2099-2110
37. Yang C., and Kazanietz M.G. Divergence and complexities in DAG signaling: looking beyond PKC. Trend Pharmacol Sci 24 (2003) 602-608
38. Gonzalez-Guerrico A.M., Meshki J., Xiao L., Benavides F., Conti C.J., and Kazanietz M.G. Molecular mechanisms of protein kinase C-induced apoptosis in prostate cancer cells. J Biochem Mol Biol 38 (2005) 639-645
39. Guo J., Zhu T., Xiao Z.X., and Chen C.Y. Modulation of intracellular signaling pathways to induce apoptosis in prostate cancer cells. J Biol Chem 282 (2007) 24364-24372
40. Gonzalez-Guerrico A.M., and Kazanietz M.G. Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase C delta. J Biol Chem 280 (2005) 38982-38991
41. Powell C.T., and Yin L. Overexpression of PKC epsilon sensitizes LNCaP human prostate cancer cells to induction of apoptosis by bryostatin 1. Int J Cancer 118 (2006) 1572-1576
42. Gavrielides M.V., Gonzalez-Guerrico A.M., Riobo N.A., and Kazanietz M.G. Androgens regulate protein kinase Cdelta transcription and modulate its apoptotic function in prostate cancer cells. Cancer Res 66 (2006) 11792-11801
43. Tanaka Y., Gavrielides M.V., Mitsuuchi Y., Fujii T., and Kazanietz M.G. Protein kinase C promotes apoptosis in LNCaP prostate cancer cells through activation of p38 MAPK and inhibition of the Akt survival pathway. J Biol Chem 278 (2003) 33753-33762
44. Ali S., Aranha O., Li Y., Pettit G.R., Sarkar F.H., and Philip P.A. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1. Cancer Chemoth Pharm 52 (2003) 235-246
45. Jarzabek K., Laudanski P., Dzieciol J., Dabrowska M., and Wolczynski S. Protein kinase C involvement in proliferation and survival of breast cancer cells. Folia Histochem Cytobiol 40 (2002) 193-194
46. Sliva D., English D., Lyons D., and Lloyd Jr. F.P. Protein kinase C induces motility of breast cancers by upregulating secretion of urokinase-type plasminogen activator through activation of AP-1 and NF-kappaB. Biochem Biophys Res Commun 290 (2002) 552-557
47. Liu D.S., Krebs C.E., and Liu S.J. Proliferation of human breast cancer cells and anti-cancer action of doxorubicin and vinblastine are independent of PKC-alpha. J Cell Biochem 101 (2007) 517-528
48. Li H., and Weinstein I.B. Protein kinase C beta enhances growth and expression of cyclin D1 in human breast cancer cells. Cancer Res 66 (2006) 11399-11408
49. Sledge Jr. G.W., and Gokmen-Polar Y. Protein kinase C-beta as a therapeutic target in breast cancer. Semin Oncol 33 (2006) S15-S18
50. Nabha S.M., Glaros S., Hong M., et al. Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24 (2005) 3166-3176
51. Karp G., Maissel A., and Livneh E. Hormonal regulation of PKC: estrogen up-regulates PKC eta expression in estrogen-responsive breast cancer cells. Cancer Lett 246 (2007) 173-181
52. Chen Z.F., Fang J.Y., Weng Y.R., Sun D.F., Wang X., and Lu R. The effect of PKC-delta inhibitor Rottlerin on human colon cancer cell line SW1116 and its mechanism. Zhonghua Zhong Liu Za Zhi 28 (2006) 564-567
53. Cerda S.R., Mustafi R., Little H., et al. Protein kinase C delta inhibits Caco-2 cell proliferation by selective changes in cell cycle and cell death regulators. Oncogene 25 (2006) 3123-3138
54. Wang Q., Zhou Y., and Evers B.M. Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells. Neoplasia 8 (2006) 781-787
55. Kern M., Pahlke G., Balavenkatraman K.K., Bohmer F.D., and Marko D. Apple polyphenols affect protein kinase C activity and the onset of apoptosis in human colon carcinoma cells. J Agric Food Chem 55 (2007) 4999-5006
56. Kern M., Tjaden Z., Ngiewih Y., et al. Inhibitors of the epidermal growth factor receptor in apple juice extract. Mol Nutr Food Res 49 (2005) 317-328
57. Mustafi R., Cerda S., Chumsangsri A., Fichera A., and Bissonnette M. Protein kinase-zeta inhibits collagen I-dependent and anchorage-independent growth and enhances apoptosis of human Caco-2 cells. Mol Cancer Res 4 (2006) 683-694
58. Ozpolat B., Akar U., Mehta K., and Lopez-Berestein G. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. Autophagy 3 (2007) 480-483
59. El F.J., Su Y., Buchler P., et al. PKC 412 small-molecule tyrosine kinase inhibitor: single-compound therapy for pancreatic cancer. Cancer 110 (2007) 1457-1468
60. Wu T.T., Hsieh Y.H., Wu C.C., Hsieh Y.S., Huang C.Y., and Liu J.Y. Overexpression of protein kinase C alpha mRNA in human hepatocellular carcinoma: a potential marker of disease prognosis. Clin Chim Acta 382 (2007) 54-58
61. Wu T.T., Hsieh Y.H., Hsieh Y.S., and Liu J.Y. Reduction of PKC alpha decreases cell proliferation, migration, and invasion of human malignant hepatocellular carcinoma. J Cell Biochem 103 (2007) 9-20
62. Hsieh Y.H., Wu T.T., Huang C.Y., Hsieh Y.S., Hwang J.M., and Liu J.Y. p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res 67 (2007) 4320-4327
63. Wen-Sheng W., and Jun-Ming H. Activation of protein kinase C alpha is required for TPA-triggered ERK (MAPK) signaling and growth inhibition of human hepatoma cell HepG2. J Biomed Sci 12 (2005) 289-296
64. Takai S., Matsushima-Nishiwaki R., Tokuda H., et al. Protein kinase C delta regulates the phosphorylation of heat shock protein 27 in human hepatocellular carcinoma. Life Sci 81 (2007) 585-591
65. Datta K., Li J., Bhattacharya R., Gasparian L., Wang E., and Mukhopadhyay D. Protein kinase C zeta transactivates hypoxia-inducible factor alpha by promoting its association with p300 in renal cancer. Cancer Res 64 (2004) 456-462
66. Li J., and Gobe G. Protein kinase C activation and its role in kidney disease. Nephrology (Carlton) 11 (2006) 428-434
67. Brenner W., Farber G., Herget T., Wiesner C., Hengstler J.G., and Thuroff J.W. Protein kinase C eta is associated with progression of renal cell carcinoma (RCC). Anticancer Res 23 (2003) 4001-4006
68. Brenner W., Greber I., Gudejko-Thiel J., et al. Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase. Int J Oncol 32 (2008) 1125-11231
69. Brenner W., Benzing F., Gudejko-Thiel J., et al. Regulation of beta1 integrin expression by PKC epsilon in renal cancer cells. Int J Oncol 25 (2004) 1157-1163
70. Weisberg E., and Griffin J.D. Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients. Drug Resist Update 4 (2001) 22-28
71. Rizvi M.A., Ghias K., Davies K.M., et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 5 (2006) 1783-1789
72. Mizuno K., Saido T.C., Ohno S., Tamaoki T., and Suzuki K. Staurosporine-related compounds, K252a and UCN-01, inhibit both cPKC and nPKC. FEBS Lett 330 (1993) 114-116
73. Smith J.B., Smith L., and Pettit G.R. Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem Biophys Res Commun 132 (1985) 939-945
74. Philip P.A., and Zonder J.A. Pharmacology and clinical experience with bryostatin 1: a novel anticancer drug. Expert Opin Invest Drug 8 (1999) 2189-2199
75. El-Rayes B.F., Gadgeel S., Shields A.F., Manza S., Lorusso P., and Philip P.A. Phase I study of bryostatin 1 and gemcitabine. Clin Cancer Res 12 (2006) 7059-7062
76. Lin J.K. Molecular targets of curcumin. Adv Exp Med Biol 595 (2007) 227-243
77. Singh S., and Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agent Med Chem 6 (2006) 259-270
78. Kunnumakkara A.B., Anand P., and Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett (2008)
79. Bastianetto S., Brouillette J., and Quirion R. Neuroprotective effects of natural products: interaction with intracellular kinases, amyloid peptides and a possible role for transthyretin. Neurochem Res 32 (2007) 1720-1725
80. Advani R., Peethambaram P., Lum B.L., et al. A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. Cancer 100 (2004) 321-326
81. Alberts S.R., Schroeder M., Erlichman C., et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a north central cancer treatment group phase II trial. J Clin Oncol 22 (2004) 4944-4950
82. Paz-Ares L., Douillard J.Y., Koralewski P., et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 24 (2006) 1428-1434
83. Horgan K., Cooke E., Hallett M.B., and Mansel R.E. Inhibition of protein kinase C mediated signal transduction by tamoxifen Importance for antitumour activity. Biochem Pharmacol 35 (1986) 4463-4465
84. Gundimeda U., Chen Z.H., and Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 271 (1996) 13504-13514
85. Dhillon N., Aggarwal B.B., Li L., Chiao P.S.F., Wolff R.A., and Kurzrock R. Phase II trial of curcumin (diferuloyl methane0, an NF-kB inhibitor, in patients with advanced pancreatic cancer. J Clin Oncol (2006) 24
86. Vadhan V.S., Weber D., Giralt S., et al. Curcumin downregulates NF-kB and related genes in patients with multiple myeloma: results of a phase1/2 study. Am Soc Hematol (2007)